Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I. Mosenzon O, et al. Among authors: stahre c. Diabetes Care. 2017 Jan;40(1):69-76. doi: 10.2337/dc16-0621. Epub 2016 Oct 17. Diabetes Care. 2017. PMID: 27797925 Free article. Clinical Trial.
Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.
Leiter LA, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, Hoekstra JB, Alvarsson M, Im K, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Leiter LA, et al. Among authors: stahre ca. Diabetes Obes Metab. 2016 Feb;18(2):186-90. doi: 10.1111/dom.12582. Epub 2015 Nov 27. Diabetes Obes Metab. 2016. PMID: 26443993 Clinical Trial.
Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, Im K, Stahre C, Buskila A, Iqbal N, Greenberger N, Lerch MM. Raz I, et al. Among authors: stahre c. Diabetes Care. 2014 Sep;37(9):2435-41. doi: 10.2337/dc13-2546. Epub 2014 Jun 9. Diabetes Care. 2014. PMID: 24914244 Clinical Trial.
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, Smahelova A, Hirshberg B, Stahre C, Frederich R, Bonnici F, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Leiter LA, et al. Among authors: stahre c. Diabetes Care. 2015 Jun;38(6):1145-53. doi: 10.2337/dc14-2868. Epub 2015 Mar 10. Diabetes Care. 2015. PMID: 25758769 Clinical Trial.
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.
Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, Bhatt DL, Raz I. Mosenzon O, et al. Among authors: stahre c. Diabetes Care. 2015 Nov;38(11):2142-50. doi: 10.2337/dc15-1068. Epub 2015 Sep 10. Diabetes Care. 2015. PMID: 26358285 Clinical Trial.
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.
Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Sjostrand M, Stahre C, Im K, Kanevsky E, Scirica BM, Bhatt DL, Braunwald E. Cahn A, et al. Among authors: stahre c. Diabetes Care. 2016 Aug;39(8):1329-37. doi: 10.2337/dc15-2763. Epub 2016 May 23. Diabetes Care. 2016. PMID: 27222508 Clinical Trial.
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.
Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E. Scirica BM, et al. Among authors: stahre c. JAMA Cardiol. 2018 Feb 1;3(2):155-163. doi: 10.1001/jamacardio.2017.4228. JAMA Cardiol. 2018. PMID: 29214305 Free PMC article. Clinical Trial.
15 results